EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of LANXESS Aktiengesellschaft, a specialty chemicals company $37.85, price $17.19, upside +120.2%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Basic Materials · US · Home Germany · ISIN DE0005470405

LA LANXESS Aktiengesellschaft, a specialty chemicals company logo Some data Sep 24, 2026

LANXESS Aktiengesellschaft, a specialty chemicals company

LNXSF · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $37.85 · Strongly undervalued (+120.2%)
!Quality 42/100
!Weak Growth (revenue 5y −1.5 %/yr)
!Loss-making · -12.1% net margin (TTM)
!Moderate debt · negative free cash flow
!0.6% dividend yield · Token dividend
!Narrow moat 18/100
!Evidence only medium, so the estimate is less certain
Watch LANXESS Aktiengesellschaft, a specialty chemicals company, for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$79.07 $13.51 Fair Value $37.85 Jun 2015 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $13.51 – $79.07 · fair‑value band $21.38 – $54.32 · the $17.19 price screens below the $37.85 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LANXESS, a specialty chemicals company, engages in the development, manufacture, and marketing of chemical intermediates, additives, and consumer protection products worldwide. It operates through three segments: Consumer Protection, Specialty Additives, and Advanced Intermediates.

Show more

LANXESS, a specialty chemicals company, engages in the development, manufacture, and marketing of chemical intermediates, additives, and consumer protection products worldwide. It operates through three segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. The company provides material protection products; disinfectant, hygiene, and preservative solutions; flavors and fragrances; liquid purification technologies for the treatment of water and other liquids; and precursors and intermediates for the agrochemicals, pharmaceuticals, and specialty chemicals industries. It also offers additives, lubricants, flame retardants, plasticizers, and bromine derivatives for various rubber, plastic and paint, electrical/electronics, and construction industries. In addition, the company provides basic and fine chemicals, organometallics, and inorganic pigments for the coloring of construction materials, as well as paints and coatings. It serves the energy, natural resources, industrial applications, nutrition, health, consumer goods, agriculture, animal health, construction, chemicals, and mobility industries. LANXESS was founded in 1863 and is headquartered in Cologne, Germany.

Stock analysis

LANXESS Aktiengesellschaft, a specialty chemicals company, (LNXSF) currently trades at $17.19, while our model-based Fair Value estimate is $37.85, implying the stock looks roughly 54.6% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $46.86 per share, and 2 of the 4 models we run sit above the $17.19 price.

Bear case: the Asset-Based group reads lowest at $30.52, and 2 of the 4 models stay below the price. Evidence for this calculation is medium.

Scenario range: $21.38 (bear) to $54.32 (bull), the price of $17.19 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

LANXESS Aktiengesellschaft, a specialty chemicals company, reported revenue of €5.7B in FY2025 versus €7.6B in FY2021, a compound −6.9%/yr. Reported net income was −€577M in FY2025.

Key figures

Market cap $1.5B · P/S ratio 0.28 · EPS (TTM) $−8.88 · Dividend yield 0.6% · Net margin −10.2% · Return on equity −16.8% · Return on assets (EBIT) −0.4% · Operating margin −2.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at 120%, LNXSF screens cheaper than that median.

Fair Value models

Bear $21.38 Fair Value $37.85 Bull $54.32
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM $1.01 $1.09 $1.21 69
DDM Multi-Stage $1.01 $1.21 $1.45 67
EV/EBITDA $30.66 $46.86 $63.05 66
All 4 models by family
Dividend Discount
Gordon GGM $1.01 $1.09 $1.21 69
DDM Multi-Stage $1.01 $1.21 $1.45 67
Multiples
EV/EBITDA $30.66 $46.86 $63.05 66
Asset-Based
NCAV (Graham) $22.77 $30.52 $45.55 54

Open the full fair value analysis →

Notify me when LNXSF reaches fair value

Put LNXSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 40 · Market factors (momentum, volatility) 20

Profitability 15
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 14
Earnings quality: real cash, not paper profit
Fin. Strength 36
Balance sheet, leverage, solvency risk
Investment 93
Disciplined investing over empire-building
Low Volatility 25
Calm price path (market factor)
Momentum 24
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 1/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−10.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic). Over 10 years: −3.3% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.1% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LNXSF, get fair value alerts →

Compare LANXESS Aktiengesellschaft, a specialty chemicals company, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 691 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside +113.1% · Top 25%
Profitability
Return on assets −1.1% · Bottom 25%
Net margin (TTM) −12.1% · Bottom 25%
Operating margin (TTM) −2.9% · Bottom 25%
Growth and dividend
Revenue growth −13.9% · Bottom 25%
Dividend yield (TTM) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.51× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 0.43× · Cheapest 25%
P/S (TTM) 0.28× · Cheapest 25%
EV/EBITDA 9.6× · Cheaper than median
PEG 1.13× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $474.65 $441.72 −7%
The Sherwin-Williams Company SHW $330.44 $151.68 −54%
Ecolab Inc ECL $274.58 $96.56 −65%
Air Products and Chemicals, Inc APD $279.19 $121.30 −57%
Nan Ya Plastics Corporation 1303 238.00 TWD 234.23 TWD −2%
Givaudan SA GIVN CHF 3,360 CHF 1,527 −55%
Wanhua Chemical Group 600309 ¥69.45 ¥68.03 −2%
DSM-Firmenich AG DSFIR CHF 92.30 CHF 29.70 −68%
Asian Paints Limited ASIANPAINT ₹2,444 ₹1,479 −39%
PPG Industries, Inc PPG $104.67 $76.98 −26%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LANXESS Aktiengesellschaft, a specialty chemicals company, · Fair Value
$37.85 +55%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LANXESS Aktiengesellschaft, a specialty chemicals company, Fair Value". https://www.fairvalue-calculator.com/stock/LNXSF

Frequently asked questions

Is LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $37.85 versus a price of $17.19, about +120% upside (undervalued).
What is the fair value of LNXSF?
Our model-based fair value for LANXESS Aktiengesellschaft, a specialty chemicals company, is $37.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: $17.19.
What is the quality score of LNXSF?
LANXESS Aktiengesellschaft, a specialty chemicals company, has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Our model-based price target is the fair value of $37.85 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario $21.38, optimistic scenario $54.32. It is a calculation from audited fundamentals, not an analyst target.
What is the LANXESS Aktiengesellschaft, a specialty chemicals company, stock forecast for 2026?
Our models put fair value at $37.85, about +120% upside versus a price of $17.19 (undervalued). Cautious scenario $21.38, optimistic scenario $54.32. The calculation is refreshed regularly with new filings.
What is the revenue of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
LANXESS Aktiengesellschaft, a specialty chemicals company, reported trailing-twelve-month revenue of about €5.4B (latest available figure, as of Sep 24, 2026).
Does LANXESS Aktiengesellschaft, a specialty chemicals company, pay a dividend?
LANXESS Aktiengesellschaft, a specialty chemicals company, currently shows a dividend yield of about 0.58% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LANXESS Aktiengesellschaft, a specialty chemicals company, it is $37.85 per share (as of Sep 24, 2026), against a price of $17.19. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is LANXESS Aktiengesellschaft, a specialty chemicals company, stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LNXSF trades below its calculated fair value: price $17.19, fair value $37.85, a gap of about +120% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LNXSF?
No. The price is what the market pays today ($17.19); the fair value is what the company's own numbers justify ($37.85). For LANXESS Aktiengesellschaft, a specialty chemicals company, the two are $20.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is LANXESS Aktiengesellschaft, a specialty chemicals company, worth?
The market values LANXESS Aktiengesellschaft, a specialty chemicals company, at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $17.19; our models calculate a fair value of $37.85 per share.
What do the bullish and bearish scenarios say about LNXSF?
Our models span a range for LANXESS Aktiengesellschaft, a specialty chemicals company,: cautious scenario $21.38, base $37.85, optimistic $54.32 per share (as of Sep 24, 2026, price $17.19). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of LNXSF?
The PEG ratio of LANXESS Aktiengesellschaft, a specialty chemicals company, is 1.13 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Balance-sheet figures for LANXESS Aktiengesellschaft, a specialty chemicals company, (as of Sep 24, 2026): return on equity −16.8%, debt of 0.51 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is LNXSF from its 52-week high?
LANXESS Aktiengesellschaft, a specialty chemicals company, trades at $17.19, about 32% below its 52-week high of $25.45 and 27% above the low of $13.51 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $37.85 is for.
Which stocks are comparable to LANXESS Aktiengesellschaft, a specialty chemicals company,?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LANXESS Aktiengesellschaft, a specialty chemicals company, stock attractive at the current price?
The data as of Sep 24, 2026: price $17.19, calculated fair value $37.85 (+120%), Quality Score 42/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LNXSF calculated?
We run LANXESS Aktiengesellschaft, a specialty chemicals company, through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $37.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. LANXESS Aktiengesellschaft, a specialty chemicals company, currently trades 55 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The closing price on Oct 2, 2026 was $17.19. Our model-based fair value is $37.85, about +120% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LANXESS Aktiengesellschaft, a specialty chemicals company, right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($21.38). The market is more pessimistic than our downside scenario. A fairly wide model range ($21.38 to $54.32) leaves room in how you read the outcome.

Key figures of LANXESS Aktiengesellschaft, a specialty chemicals company,

How large is the market capitalisation of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The market capitalisation of LANXESS Aktiengesellschaft, a specialty chemicals company, is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The price-to-sales ratio of LANXESS Aktiengesellschaft, a specialty chemicals company, is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Earnings per share at LANXESS Aktiengesellschaft, a specialty chemicals company, are $−8.88. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The dividend yield of LANXESS Aktiengesellschaft, a specialty chemicals company, is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The net margin of LANXESS Aktiengesellschaft, a specialty chemicals company, is −10.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The return on equity (ROE) of LANXESS Aktiengesellschaft, a specialty chemicals company, is −16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
On an EBIT basis the return on assets of LANXESS Aktiengesellschaft, a specialty chemicals company, is −0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
The operating margin of LANXESS Aktiengesellschaft, a specialty chemicals company, is −2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Revenue at LANXESS Aktiengesellschaft, a specialty chemicals company, is growing −13.9% versus a year earlier (3y avg −11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF)?
Earnings per share at LANXESS Aktiengesellschaft, a specialty chemicals company, are growing +13.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF) generate?
The free cash flow of LANXESS Aktiengesellschaft, a specialty chemicals company, is −€56.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LANXESS Aktiengesellschaft, a specialty chemicals company (LNXSF) carry?
The net debt of LANXESS Aktiengesellschaft, a specialty chemicals company, is €2.1B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch LANXESS Aktiengesellschaft, a specialty chemicals company, in the live analysis

One click puts LANXESS Aktiengesellschaft, a specialty chemicals company, on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.